Tempus Expands Precision Oncology Partnerships with Northwestern Medicine and NYU Langone Health
Key Insights
Tempus (search) AI has formed strategic collaborations with Northwestern Medicine and NYU Langone Health to expand genomic testing access for cancer patients across all stages and types.
Northwestern Medicine will now offer next-generation sequencing to early-stage cancer patients, substantially augmenting their existing precision oncology capabilities.
NYU Langone Health partnership includes launching a prospective observational study for serial molecular profiling throughout patients' treatment journeys.
Tempus (search) AI, Inc. (NASDAQ: TEM) has announced two major strategic partnerships that will significantly expand access to genomic testing for cancer patients at leading academic medical centers. The collaborations with Northwestern Medicine and NYU Langone Health represent a substantial advancement in precision oncology capabilities, bringing comprehensive molecular profiling to broader patient populations.
Northwestern Medicine Partnership Extends Testing to Early-Stage Patients
The collaboration between Northwestern Medicine and Tempus (search) focuses specifically on expanding genomic testing access across the oncology patient population, with particular emphasis on early-stage cancer diagnoses. This partnership will provide nearly every patient across cancer types access to genomic testing, enabling clinicians to deploy tailored, effective treatments based on a deeper understanding of each patient's unique cancer profile.
"The collaboration with Tempus (search) will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage cancers," said Dr. Howard Chrisman, President and CEO of Northwestern Memorial HealthCare. "The data generated from this approach will allow us to rapidly adopt novel treatments and facilitate the design of innovative clinical trials aimed at developing personalized cancer treatments."
Northwestern Medicine provides comprehensive cancer care and is home to The Robert H. Lurie Comprehensive Cancer Center (search) of Northwestern University, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and founding member of the National Comprehensive Cancer Network (search) (NCCN). As part of the collaboration, Tempus (search) will provide access to its comprehensive genomic testing portfolio, including solid tissue, DNA and RNA profiling, liquid biopsy, and minimal residual disease (MRD) testing.
NYU Langone Health Research Initiative Focuses on Serial Molecular Profiling
The multi-year strategic collaboration with NYU Langone Health takes a research-focused approach, supporting the Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center (search) through a comprehensive, pan-cancer initiative designed to understand disease biology over time. This partnership aims to enhance genomic diagnostics to improve patient outcomes, inform future clinical practice, and accelerate the development and validation of novel assays and algorithmic diagnostics.
Central to this collaboration is the launch of a prospective observational study titled "Serial Molecular Profiling and Monitoring of Human Cancer." Patients enrolled in the study will undergo sequencing throughout their treatment journey to collect longitudinal data critical to advancing precision oncology research. The collaboration includes subsequent studies focused on assay validation, biomarker discovery, biological modeling, real-world data analysis, and the development of AI-powered predictive algorithms.
"Through the integration of advanced genomic technologies and data science, we are deepening our understanding of cancer's complexity and pioneering transformative approaches for patient monitoring and treatment," said Dr. Ezra Cohen, Chief Medical Officer, Oncology at Tempus (search). "Our research is focused on generating actionable insights through better understanding of cancer response, resistance, and trajectory that will not only refine and enhance current assays, but also drive the creation of innovative diagnostic tools and algorithms that can empower clinicians to deliver truly individualized care to their patients."
Advancing Targeted Therapy Development
Dr. Shridar Ganesan, Director of the Center for Molecular Oncology at Perlmutter Cancer Center, emphasized the clinical implications of the collaboration: "This strategic collaboration will further our ability to analyze cutting-edge serial molecular profiling technology in the routine care of patients at the Perlmutter Cancer Center at NYU Langone Health. This approach will enable us to better understand the biology of individual cancers, inform our ability to implement and develop targeted therapies, and assess response and emerging resistance."
Both partnerships leverage Tempus (search)'s position as a technology company advancing precision medicine through artificial intelligence applications in healthcare. The company maintains one of the world's largest libraries of multimodal data and provides an operating system to make that data accessible and useful for AI-enabled precision medicine solutions.
Eric Lefkofsky, Founder and CEO of Tempus (search), stated: "This collaboration will deliver on our shared mission of driving the field of cancer testing forward by bringing the benefits of genomic testing to as broad a population as possible. With one of the industry's most comprehensive genomic portfolios and the operational infrastructure to support broad adoption, we look forward to supporting Northwestern Medicine in delivering more precise, personalized cancer care for their patients."
These strategic partnerships position both academic medical centers to advance precision oncology through comprehensive molecular profiling, potentially transforming cancer care delivery and accelerating the development of personalized treatment approaches for patients across all cancer stages and types.